<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7360125\results\search\testTrace\results.xml">
  <result pre="Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2" exact="infection" post="and its treatment http://orcid.org/0000-0003-3224-1151ShahSanketsanketimmunology@gmail.com1http://orcid.org/0000-0002-2121-0942DandaDebashishdebashish.danda@cmcvellore.ac.in2http://orcid.org/0000-0002-3643-3989KavadichandaChengappadoc.chengappa@gmail.com1http://orcid.org/0000-0002-3153-4166DasSaibalsaibaldas123@gmail.com3http://orcid.org/0000-0001-8091-1952AdarshM. B.adarshmb@gmail.com1http://orcid.org/0000-0003-1518-6031NegiVir Singhvsnegi22@yahoo.co.in1[1], grid.414953.e0000000417678301Department of Clinical"/>
  <result pre="musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its" exact="treatment" post="http://orcid.org/0000-0003-3224-1151ShahSanketsanketimmunology@gmail.com1http://orcid.org/0000-0002-2121-0942DandaDebashishdebashish.danda@cmcvellore.ac.in2http://orcid.org/0000-0002-3643-3989KavadichandaChengappadoc.chengappa@gmail.com1http://orcid.org/0000-0002-3153-4166DasSaibalsaibaldas123@gmail.com3http://orcid.org/0000-0001-8091-1952AdarshM. B.adarshmb@gmail.com1http://orcid.org/0000-0003-1518-6031NegiVir Singhvsnegi22@yahoo.co.in1[1], grid.414953.e0000000417678301Department of Clinical Immunology, Jawaharlal Institute"/>
  <result pre="many other viral infections, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)" exact="infection" post="can potentially lead to an array of rheumatological and"/>
  <result pre="the myriad of antiviral drugs presently being tried in the" exact="treatment" post="of COVID-19 can result in several rheumatic musculoskeletal adverse"/>
  <result pre="still on the rise. Moreover, with no vaccine or definitive" exact="treatment" post="in sight [2], the health care systems across the"/>
  <result pre="is a mammoth event in the history of humankind. The" exact="infection" post="has spread across all large countries affecting people from"/>
  <result pre="large countries affecting people from all age groups. Such an" exact="infection" post="is likely to have long-term consequences, and RMDs could"/>
  <result pre="to treat existing rheumatic diseases and about the outcome of" exact="infection" post="among those on immunosuppressive agents. This and many more"/>
  <result pre="general population [20]. Spectrum of rheumatic musculoskeletal manifestations of SARS-CoV-2" exact="infection" post="and antiviral drugs With scientific literature pouring in from"/>
  <result pre="classical features of myocarditis. Improvement of myocarditis was noticed following" exact="treatment" post="with hydroxychloroquine, lopinavir/ritonavir, and intravenous methylprednisolone [25, 26]. An"/>
  <result pre="immune dysregulation. Table 1 Rheumatic musculoskeletal manifestations associated with SARS-CoV-2" exact="infection" post="Reported with SARS-CoV-2 Clinical characteristics Refs. Musculoskeletal manifestations Â"/>
  <result pre="Cytokine storm/Secondary Hemophagocytic lymphohistiocytosis (sHLH) Represents critical patients with SARS-CoV-2" exact="infection" post="After 8â€&quot;9Â days of the symptom onset Unremitting fever,"/>
  <result pre="mortality H-score ofâ€‰&amp;gt;â€‰169, 93% sensitivity and 86% specificity for the" exact="diagnosis" post="of the sHLH Report on improvement with IL-1 and"/>
  <result pre="MAA myositis-associated autoantibodies, MSA myositis-specific autoantibodies, RA rheumatoid arthritis, PCR" exact="polymerase chain reaction," post="SARS-CoV-2 severe acute respiratory syndrome coronavirus-2 Based on evidence"/>
  <result pre="special mention. Myopathy and neuromyopathy can rarely occur following long-term" exact="treatment" post="with chloroquine and hydroxychloroquine [33]. Favipiravir can lead to"/>
  <result pre="in addition to anticoagulants in severe COVID-19 cases [44]. SARS-CoV-2" exact="infection" post="and autoimmunity The interplay of various genetic, hormonal, immunological,"/>
  <result pre="describe some of the possible mechanism of autoimmunity following SARS-CoV-2" exact="infection" post="as follows: Table 3 Mechanisms of autoimmune manifestation following"/>
  <result pre="immunodeficiency virus Autoantibodies in AIDS Influenza Acute disseminated encephalomyelitis Persistent" exact="infection" post="and polyclonal activation Epstein-Barr virus Lymphoproliferation Hepatitis C virus"/>
  <result pre="be due to a similar autoreactive adaptive response with SARS-CoV-2" exact="infection" post="[3]. The role of genetic susceptibility should also be"/>
  <result pre="accumulation of the primed lymphocytes at the site of viral" exact="infection" post="[71]. These preferentially accumulated lymphocytes exhibit increased activity as"/>
  <result pre="[75]. Persistent immune activation The third theory of persistent viral" exact="infection" post="and oligo/polyclonal activation can be explained by the constant"/>
  <result pre="[81]. In COVID-19, a rise in neutrophil counts during early" exact="infection" post="is a poor prognostic factor. The migration of these"/>
  <result pre="has taken place in the human behavior with advocacy of" exact="social distancing," post="handwashing, use of mask and gloves, and movement restrictions"/>
  <result pre="This may reduce the occurrence of subsequent effects of influenza" exact="infection" post="on RMDs. Diseases like acute rheumatic fever, where overcrowding"/>
  <result pre="Currently, a multitude of vaccines for the prevention of SARS-CoV-2" exact="infection" post="is under investigation [90]. Except for the nucleocapsid, all"/>
  <result pre="the risk of pathogenic priming. Targeted immunosuppressive therapy for SARS-CoV-2" exact="infection" post="The clinical outcome of the patients relies on the"/>
  <result pre="as from the infiltrating lymphocytes and monocytes [99]. The anti-IL-6" exact="treatment" post="strategy has shown efficacy in a similar CRS-like phenomenon"/>
  <result pre="is no ongoing clinical trial registered at present for the" exact="treatment" post="of COVID-19. (1) TLR7 mediated viral signaling at the"/>
  <result pre="illnesses that could be triggered due to COVID-19 or the" exact="treatment" post="for the same. This information may help the rheumatology"/>
  <result pre="in the effective management of the rheumatic manifestations of SARS-CoV-2" exact="infection" post="in the post-COVID-19 era. Publisher's Note Springer Nature remains"/>
  <result pre="(2020) Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus" exact="infection" post="therapy?Clin Sci Lond Engl1979134554354510.1042/CS20200163 12.HammingITimensWBulthuisMLelyANavisGvan GoorHTissue distribution of ACE2"/>
  <result pre="27.MehtaPMcAuleyDFBrownMSanchezETattersallRSMansonJJCOVID-19: consider cytokine storm syndromes and immunosuppressionLancet2020395102291033103410.1016/S0140-6736(20)30628-032192578 28.GazzarusoCCarlo StellaNMarianiGet al.High" exact="prevalence" post="of antinuclear antibodies and lupus anticoagulant in patients hospitalized"/>
  <result pre="Wuhan, China: a retrospective cohort studyLancet Lond Engl2020395102291054106210.1016/S0140-6736(20)30566-3 32.EspositoSNovielloSPaglianoPUpdate on" exact="treatment" post="of COVID-19: ongoing studies between promising and disappointing resultsInfez"/>
  <result pre="inhibitors in clinical developmentCurr Opin Infect Dis201932217618610.1097/QCO.000000000000053230724789 35.ChandwaniAShuterJLopinavir/ritonavir in the" exact="treatment" post="of HIV-1 infection: a reviewTher Clin Risk Manag2008451023103319209283 36.NaikGSTyagiMGA"/>
  <result pre="InfectionJ Clin Exp Hepatol201221425410.1016/S0973-6883(12)60090-525755405 37.PsarrasAEmeryPVitalEMType I interferonâ€&quot;mediated autoimmune diseases: pathogenesis," exact="diagnosis" post="and targeted therapyRheumatology201756101662167510.1093/rheumatology/kew43128122959 38.TangNLiDWangXSunZAbnormal coagulation parameters are associated with"/>
  <result pre="Thromb201425320621610.1097/MBC.0000000000000065 43.ZuoYZuoMYalavarthiSet al.Neutrophil extracellular traps and thrombosis in COVID-19MedRxiv202010.1101/2020.04.30.2008673632587992 44.TangNBaiHChenXGongJLiDSunZAnticoagulant" exact="treatment" post="is associated with decreased mortality in severe coronavirus disease"/>
  <result pre="Neurosci201810.3389/fnmol.2018.0011629695953 49.TanayAChikungunya virus and autoimmunityCurr Opin Rheumatol201729438939310.1097/BOR.000000000000039628376065 50.Fausther-BovendoHQiuXMcCorristerSet al.Ebola virus" exact="infection" post="induces autoimmunity against dsDNA and HSP60Sci Rep201774214710.1038/srep4214728181533 51.FujinamiRSvon HerrathMGChristenUWhittonJLMolecular"/>
  <result pre="in WuhanChina The Lancet20203951022349750610.1016/S0140-6736(20)30183-5 73.KimJYKoJHKimYet al.Viral load kinetics of SARS-CoV-2" exact="infection" post="in first two patients in KoreaJ Korean Med Sci2020357e8610.3346/jkms.2020.35.e8632080991"/>
  <result pre="Immunosuppressed States: a clinical-therapeutic staging proposalJ Heart Lung Transpl202010.1016/j.healun.2020.03.012 96.SÃ¶nmezHEDemirSBilginerYÃ–zenSAnakinra" exact="treatment" post="in macrophage activation syndrome: a single center experience and"/>
  <result pre="adult-onset stillâ€™s disease: a case-based reviewCase Rep Med20162016565632010.1155/2016/565632027688774 101.XuXHanMLiTet al.Effective" exact="treatment" post="of severe COVID-19 patients with tocilizumabProc Natl Acad Sci202011720109701097510.1073/pnas.200561511732350134"/>
 </snippets>
</snippetsTree>
